Literature DB >> 20842540

Considerations in developing a target product profile for parenteral pharmaceutical products.

William J Lambert1.   

Abstract

A target product profile (TPP) describes how a product will be utilized by the end user. A systematically developed TPP can ensure alignment of objectives across company departments, accelerate development timelines, minimize development risks, and eventually lead to an optimal product. A TPP is particularly important for parenteral products due to the need for administration devices, the variety of possible end users (nurses, patients, pharmacists, and physicians), and requirements specific to sterile products. This manuscript describes key components of a TPP from a formulation development perspective and provides guidance on practical issues common to parenteral products.

Entities:  

Mesh:

Year:  2010        PMID: 20842540      PMCID: PMC2974137          DOI: 10.1208/s12249-010-9521-x

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  10 in total

Review 1.  Parenteral formulations of small molecules therapeutics marketed in the United States (1999)--Part I.

Authors:  R G Strickley
Journal:  PDA J Pharm Sci Technol       Date:  1999 Nov-Dec

Review 2.  Parenteral formulations of small molecules therapeutics marketed in the United States (1999). Part III.

Authors:  R G Strickley
Journal:  PDA J Pharm Sci Technol       Date:  2000 Mar-Apr

Review 3.  Development pharmaceutics of microbicide formulations. Part II: formulation, evaluation, and challenges.

Authors:  Sanjay Garg; Kaustubh R Tambwekar; Kavita Vermani; Raghupathi Kandarapu; Alka Garg; Donald P Waller; Lourens J D Zaneveld
Journal:  AIDS Patient Care STDS       Date:  2003-08       Impact factor: 5.078

4.  Quality by design: concepts for ANDAs.

Authors:  Robert A Lionberger; Sau Lawrence Lee; Laiming Lee; Andre Raw; Lawrence X Yu
Journal:  AAPS J       Date:  2008-05-09       Impact factor: 4.009

5.  Compendium of excipients for parenteral formulations.

Authors:  M F Powell; T Nguyen; L Baloian
Journal:  PDA J Pharm Sci Technol       Date:  1998 Sep-Oct

6.  Compatibility of antineoplastic, antibiotic and corticosteroid drugs in intravenous admixtures.

Authors:  M P McRae; J C King
Journal:  Am J Hosp Pharm       Date:  1976-10

7.  Comparison of visual and turbidimetric methods for determining short-term compatibility of intravenous critical-care drugs.

Authors:  J F Dasta; K N Hale; G L Stauffer; M M Tschampel
Journal:  Am J Hosp Pharm       Date:  1988-11

8.  Review of excipients and pH's for parenteral products used in the United States.

Authors:  Y C Wang; R R Kowal
Journal:  J Parenter Drug Assoc       Date:  1980 Nov-Dec

9.  Human behaviour, cost-effectiveness analysis and research and development priorities: the case of a schistosomiasis vaccine.

Authors:  D B Evans; H L Guyatt
Journal:  Trop Med Int Health       Date:  1997-11       Impact factor: 2.622

10.  Physical and chemical compatibility of intravenous ciprofloxacin with other drugs.

Authors:  L K Jim
Journal:  Ann Pharmacother       Date:  1993-06       Impact factor: 3.154

  10 in total
  6 in total

Review 1.  Nanotechnology: an effective tool for enhancing bioavailability and bioactivity of phytomedicine.

Authors:  Thirumurugan Gunasekaran; Tedesse Haile; Tedele Nigusse; Magharla Dasaratha Dhanaraju
Journal:  Asian Pac J Trop Biomed       Date:  2014-05

2.  Aligning new interventions with developing country health systems: target product profiles, presentation, and clinical trial design.

Authors:  Alan Brooks; Julia K Nunes; Andrew Garnett; Robin Biellik; Didier Leboulleux; Ashley J Birkett; Christian Loucq
Journal:  Glob Public Health       Date:  2012-07-11

3.  Recombinant human G6PD for quality control and quality assurance of novel point-of-care diagnostics for G6PD deficiency.

Authors:  Maria Kahn; Nicole LaRue; Changcheng Zhu; Sampa Pal; Jack S Mo; Lynn K Barrett; Steve N Hewitt; Mitchell Dumais; Sandra Hemmington; Adrian Walker; Jeff Joynson; Brandon T Leader; Wesley C Van Voorhis; Gonzalo J Domingo
Journal:  PLoS One       Date:  2017-05-26       Impact factor: 3.240

4.  Challenges and Opportunities for Companies to Build HTA/Payer Perspectives Into Drug Development Through the Use of a Dynamic Target Product Profile.

Authors:  Ting Wang; Neil McAuslane; Wim G Goettsch; Hubert G M Leufkens; Marie L De Bruin
Journal:  Front Pharmacol       Date:  2022-07-18       Impact factor: 5.988

5.  Application of quality by design for 3D printed bone prostheses and scaffolds.

Authors:  Daniel Martinez-Marquez; Ali Mirnajafizadeh; Christopher P Carty; Rodney A Stewart
Journal:  PLoS One       Date:  2018-04-12       Impact factor: 3.240

Review 6.  The Ebola Vaccine Team B: a model for promoting the rapid development of medical countermeasures for emerging infectious disease threats.

Authors:  Michael Osterholm; Kristine Moore; Julie Ostrowsky; Kathleen Kimball-Baker; Jeremy Farrar
Journal:  Lancet Infect Dis       Date:  2015-10-30       Impact factor: 25.071

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.